A5036004609- Receptor Mechanisms and Signaling
- Renin-Angiotensin System Studies
- Aortic aneurysm repair treatments
- Galectins and Cancer Biology
- Regulation of Appetite and Obesity
- Abdominal vascular conditions and treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Influenza Virus Research Studies
- Dietary Effects on Health
- Chronic Kidney Disease and Diabetes
- Pulmonary Hypertension Research and Treatments
- T-cell and B-cell Immunology
- Atherosclerosis and Cardiovascular Diseases
- Cardiac Fibrosis and Remodeling
- Infectious Aortic and Vascular Conditions
- Transplantation: Methods and Outcomes
- Mitochondrial Function and Pathology
- Lipoproteins and Cardiovascular Health
- FOXO transcription factor regulation
- Computational Drug Discovery Methods
- Immune Cell Function and Interaction
- Blood Pressure and Hypertension Studies
- Adipokines, Inflammation, and Metabolic Diseases
Huazhong University of Science and Technology
2015-2024
Union Hospital
2017-2024
Union Hospital
2016-2020
Wuhan Union Hospital
2019-2020
Abstract Vaccination provides a promising approach for treatment of hypercholesterolemia and improvement in compliance. In this study, the appropriate virus-like particle (VLP)-peptide vaccines targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) were screened. The screening criteria target peptides as follows: (1) located catalytic domain PCSK9, or regulating binding PCSK9 LDL receptors (LDLR); (2) having low/no-similarity when matched with host proteome; (3) possessing ideal...
Recently, our group has developed a therapeutic hypertensive vaccine against angiotensin (Ang) II type 1 receptor (AT1R) named ATRQβ-001. To explore its potential effectiveness on streptozotocin-induced diabetic nephropathy, male Sprague Dawley rats were randomly divided into two groups: control and model. After week, the four subgroups (each with 15 rats) for 14-week treatments saline, olmesartan, ATRQβ-001, Qβ virus-like particle (VLP), respectively. In addition to lower blood pressure,...
We developed a virus-like particle (VLP)-based therapeutic vaccine against angiotensin II receptor type 1, ATR-AP205-001, which could significantly reduce the blood pressure and protect target organs of hypertensive animals. In this study, we focused on immunological effect safety VLP-based vaccine. By comparing to depolymerized dimeric ATR-Dimer-001, found that ATR-AP205-001 reached subcapsular sinus lymph node shortly after administration, followed by accumulation follicle dendritic cells...
Objective: Angiotensin II (AngII) type 1 receptor (AT1R) blockers have been proved to reduce atherosclerosis. Previously, we invented ATRQβ-001 vaccine which showed a desirable blocking effect for AT1R. The purpose of this study was investigate whether would prevent atherosclerosis in apolipoprotein E-null (ApoE–/–) mice. Methods: Male ApoE–/– mice were administered with vaccine, Qβ virus-like particles, valsartan or vehicle over period 24 weeks. In vitro, human coronary artery endothelial...
Background and Purpose Hypertension has been the leading preventable cause of premature death worldwide. The aim this study was to design a more efficient vaccine against novel targets for treatment hypertension. Experimental Approach epitope CE12, derived from human L‐type calcium channel (Ca V 1.2), designed conjugated with Qβ bacteriophage virus‐like particles test efficacy in hypertensive animals. Further, hepatitis B core antigen (HBcAg)‐CE12‐CQ10 vaccine, bivalent based on HBcAg...
Background We have developed a peptide vaccine named ATRQβ-001, which was proved to retard signal transduction initiated by angiotensin II (Ang II). Ang implicated in abdominal aortic aneurysm (AAA) progression, but whether the ATRQβ-001 would prevent AAA is unknown. Methods and Results II-infused ApoE-/- mice calcium phosphate-induced C57BL/6 were used verify efficiency of AAA. demonstrated that effectively restrained aneurysmal dilation vascular wall destruction aorta both animal models,...
The angiotensin II type 1 receptor (AT1R) signaling pathway is reported to modulate glucose metabolism. Targeting AT1R, our group invented ATRQβ-001 vaccine, a novel immunotherapeutic strategy block the activation of AT1R. Here, we evaluated therapeutic efficacy vaccine in insulin resistance, and investigated mechanism. Our results showed that specific monoclonal antibody against epitope ATR-001 (McAb-ATR) decreased fasting serum concentration improved tolerance ob/ob mice. These beneficial...
Myocardial infarction (MI), one of the most serious cardiovascular diseases, is also affected by altered mitochondrial metabolism and immune status, but their crosstalk poorly understood. In this paper, we use bioinformatics to explore key targets associated with metabolic function in MI. The datasets (GSE775, GSE183272 GSE236374) were from National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) conjunction gene data that downloaded MitoCarta 3.0 database....